Our mission is to establish new equilibriums – both in patients' immune responses and in the field of immunotherapy.As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses.Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the body's native mechanisms to restore – rather than suppress – immune balance, we aim to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated.Highlights:* Advanced clinical-stage pipeline with promising Phase II results* Short regulatory approval pathway* Multi-billion-dollar markets: Post-BMT complications , Sepsis, Solid tumors